Donald Notman | CFO |
Antony Mattessich | President and CEO |
Daniel Bollag | SVP, Regulatory Affairs, Pharmacovigilance & Quality |
Michael Goldstein | Chief Medical Officer |
Scott Corning | VP, Marketing and Commercial Operations |
Adnan Butt | Guggenheim |
Yi Chen | H.C. Wainwright |
Bill Maher | Cowen and Company |
Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeutix Q3 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.